NextGen 2024: Refractory SJIA & MAS Session Part 5

NextGen 2024: Refractory SJIA & MAS Session Part 5

@SJIA_Foundation
@SJIA_Foundation
8 Followers
2 months ago 194

International perspectives (Brazil): Presentation from Dr. Maria Teresa Terreri

NextGen 2024: Refractory SJIA & MAS Session Part 5

@SJIA_Foundation2 months ago

LVL, girl, 8 years old

SJIA diagnosis at 4 years old with typical features (fever, rash, arthritis, anemia, thrombocytosis)

Corticosteroids (including several pulse therapies) throughout the period, since 2020

MAS - IVIG, pulse therapy and cyclosporine

Currently - joint activity is maintained, using tofacitinib and leflunomide, with 17 active joints and episodes of systemic activity after infections.

Hb 11.2*; leuc 15.410 (N 65%; L 26,9%); Plaq 528,000*, ESR - 89*, CRP - 10,87*; Fibrinogen - 637*; LDH 409; Ferritine - 343

Potential alternatives:

A different anti-JAK agent? Another attempt at desensitization to tocilizumab? Association with abatacept?

LVL, girl, 8 years old
SJIA diagnosis at 4 years old with typical features 
(fever, rash, arthrit…
1/3
Tofacitinibe
Corticosteroids (including several 
pulse therapies) throughout the 
period, since …
2/3
Potential alternatives:
A different anti-JAK agent?
Another attempt at desensitization to tociliz…
3/3


  • Previous
  • Next
  • f Fullscreen
  • esc Exit Fullscreen
@SJIA_Foundation

Share

NextGen 2024: Refractory SJIA & MAS Session Part 5

Embed code


Swipe LEFT
to view Related

Scroll DOWN
to read doc

Login

OR

Forgot password?

Don't have an account? Sign Up